Bexion Pharmaceuticals, Inc. Announces Completion Of Enrollment In Open Label Portion Of ...
The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...
Intellia Therapeutics: Buy Rating Driven by Promising Efficacy and Safety of Nex-Z Treatment
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...